EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients

Jamie N Kuipers-Connarn, Arya Pourzanjani, Maitreyee Bose, Saurabh Modi, Julia Stieglmaier, Alexis Murphy, Khamir Mehta, Vijay V Upreti iD

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70074 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Jamie N Kuipers-Connarn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Modeling & Simulation, Amgen Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, T-Lymphocytes, Antineoplastic Agents, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: by Amgen Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific T‐cell engagers have revolutionized the treatment and management of hematological malignancies and more recently have started making similar strides for solid tumor indications, with opportunities to become best‐in‐ class therapeutics for cancer. Xaluritamig is a novel bivalent XmAb® 2+1 T cell engager with two STEAP1 binding sites and one CD3 binding site being developed for solid tumors with the primary indication of metastatic castrate resistant prostate cancer (mCRPC). The First‐In‐Human (FIH) study showed promising anti‐tumor activity in mCRPC patients, and the program is currently in late phase clinical development. Xaluritamig was administered as an intravenous infusion once weekly (QW) or once every other week (Q2W) in the dose escalation of the FIH study at dose levels ranging from 0.001 to 2 mg. Initial pharmacokinetic (PK) characterization of xaluritamig exhibited approximately dose‐proportional increase in exposures over the dose levels explored, with an estimated terminal half‐life of ≈9 days, assuming subjects had no anti‐drug antibodies, calculated via the population PK model. The time at which maximum concentration (C max ) occurred was typically at the end of infusion (median ≈ 1 h), as expected with IV administration. Additionally, thorough dose‐exposure‐response analyses integrated observed data and model‐based simulations of PK, key efficacy endpoints, and safety events to support the evaluation of the target doses 0.75 mg QW, 1.5 mg QW, and 1.5 mg Q2W in dose expansion. This work provides the framework for which modeling and simulations can be used to guide dose selection for dose expansion at an early stage of development adhering to the recent principles of Project Optimus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificT-LymphocytesAntineoplastic AgentsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsHumansMaleDose-Response Relationship, DrugMiddle AgedAgedInfusions, IntravenousAntigens, NeoplasmOxidoreductases

Stichwörter der Autor:innen

clinical pharmacologyclinical trialsdrug developmentmodeling and simulationoncology

Substanzen

Antibodies, BispecificAntineoplastic AgentsSTEAP1 protein, humanAntigens, NeoplasmOxidoreductases

Autor:innen und Institutionen

  • Clinical Pharmacology Modeling & Simulation, Amgen Inc., South San Francisco, California, USA.
  • Early Development Oncology, Amgen Research Munich GmbH, Munich, Germany.
  • Clinical Pharmacology Modeling & Simulation, Amgen Inc., Thousand Oaks, California, USA.

ORCID-Profile: Vijay V Upreti

Förderung

  • by Amgen Inc.

Zitieren

APA

Kuipers-Connarn, J. N., Pourzanjani, A., Bose, M., Modi, S., Stieglmaier, J., Murphy, A., Mehta, K., & Upreti, V. V. (2025). Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70074

Vancouver

Kuipers-Connarn JN, Pourzanjani A, Bose M, Modi S, Stieglmaier J, Murphy A, et al. Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70074

BibTeX
@article{KuipersConnarn2025,
  author = {Kuipers-Connarn, Jamie N and Pourzanjani, Arya and Bose, Maitreyee and Modi, Saurabh and Stieglmaier, Julia and Murphy, Alexis and Mehta, Khamir and Upreti, Vijay V},
  title = {Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70074}
}
Kostenlos starten →